Exelixis Inc logo

Exelixis Inc

EXEL
Healthcare|Biotechnology|USA
$56.51
-0.60 (-1.05%)
DCF (FCF)
$29.26
Tangible Book
$7.38
Graham Number
$23.55
Earnings Power
$17.69

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 2597.48, 2918.06, 3233.42, 3423.31, 3031.78 ], "ebit_estimate": [ 1041.09, 1170.91, 1391.19, 1582.6, 1515.67 ], "ebitda_estimate": [ 1103.59, 1209.28, 1520.63, null, null ], "net_income_estimate": [ 853.37, 961.56, 1171.22, 1401.19, 1377.05 ], "per_share_eps_estimate": [ 3.24, 3.65, 4.45, 5.37, 5.09 ], "eps_nri_estimate": [ 3.19, 3.73, 4.59, 5.44, 5.02 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 11.2, 15.03, 20.02, null, null ], "pretax_income_estimate": [ 1086.79, 1212.29, 1443.27, 1664.15, 1901.54 ], "operating_cash_flow_per_share_estimate": [ 3.26, 3.85, 5.21, 7.66, 10.61 ], "roa_estimate": [ 25.4, 24.8, 23.5, 25.8, 26.6 ], "roe_estimate": [ 30.64, 27.78, 26.65, 25.9, 26.7 ], "gross_margin_estimate": [ 96, 95.67, 95.69, 95.9, 95.88 ], "operating_cash_flow_estimate": [ 872.35, 1028.31, 1392.75, 2047.69, 2836.29 ], "pettm_estimate": [ 17.46, 15.49, 12.69, 10.52, 11.11 ], "long_term_growth_rate_mean": 18.04, "long_term_revenue_growth_rate_mean": "11.76", "future_per_share_eps_estimate_growth": 16.55, "future_eps_nri_estimate_growth": 18.04, "future_revenue_estimate_growth": 11.76, "future_ebit_estimate_growth": 16.4, "future_ebitda_estimate_growth": 18.07, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 14.21, "future_pretax_income_estimate_growth": 14.93, "future_book_value_per_share_estimate_growth": 34.44, "future_roa_estimate_growth": -4.33, "future_roe_estimate_growth": -9.16, "future_gross_margin_estimate_growth": -0.25, "future_operating_cash_flow_per_share_estimate_growth": 18.34 }
quarterly
{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 633.17, 661.27, 689.23, 697.12, 722.27, 745.3, 777.92, 802.49 ], "ebit_estimate": [ 254.07, 257.03, 250.53, 273.56, 297.5, 310.55, 274.23, null ], "ebitda_estimate": [ 262.18, 272.81, 292.69, 266.36, null, null, null, null ], "net_income_estimate": [ 202.82, 205.15, 200.38, 226.62, 240.82, 251.62, 223.57, null ], "per_share_eps_estimate": [ 0.77, 0.8, 0.81, 0.9, 0.98, 1.06, 0.69, null ], "eps_nri_estimate": [ 0.79, 0.81, 0.81, 0.9, 0.95, 0.99, 0.74, null ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ 264.63, 268.24, 265.31, 288.69, 306.89, 320.69, 285.27, null ], "operating_cash_flow_per_share_estimate": [ 0.72, 0.82, 0.7, 0.98, 0.99, 0.99, 0.73, null ], "roa_estimate": [ 7.3, 6.9, 6, null, null, null, null, null ], "roe_estimate": [ 9.3, 8.5, 7.3, null, null, null, null, null ], "gross_margin_estimate": [ 95.83, 95.77, 96.17, null, null, null, null, null ], "operating_cash_flow_estimate": [ 192.47, 217.87, 187.13, 261.98, 264.65, 264.65, 195.15, null ], "pettm_estimate": [ 17.29, 16.21, 15.06, 15.54, null, null, null, null ], "long_term_growth_rate_mean": 18.04, "long_term_revenue_growth_rate_mean": "11.76", "future_per_share_eps_estimate_growth": 16.55, "future_eps_nri_estimate_growth": 18.04, "future_revenue_estimate_growth": 11.76, "future_ebit_estimate_growth": 16.4, "future_ebitda_estimate_growth": 18.07, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 14.21, "future_pretax_income_estimate_growth": 14.93, "future_book_value_per_share_estimate_growth": 34.44, "future_roa_estimate_growth": -4.33, "future_roe_estimate_growth": -9.16, "future_gross_margin_estimate_growth": -0.25, "future_operating_cash_flow_per_share_estimate_growth": 18.34 }

News

2026-07-07 16:37:55
2026-07-07 13:01:40
2026-07-02 13:36:45
2026-07-02 12:04:16
2026-06-25 14:42:09
2026-06-24 13:35:49
2026-06-22 15:59:56
2026-06-22 13:00:10
2026-06-22 12:32:30